To cite this paper use one of the standards below:
Prediabetes is currently recognized as a relevant metabolic state, which must be urgently treated, preventing the development of diabetes and associated diseases. The estimated prevalence of diabetes in 2021 was 10.5% of the global adult population (WHO 2021). Among available medicine to treat prediabetes and, the beginning of type 2 diabetes (DM2), metformin is the first-line drug. Despite its high efficiency of metformin in reducing hyperglycemia, about 20 to 40%, there are numerous reports of undesirable side effects related to the digestive system, which include nausea, diarrhea, vomiting, abdominal discomfort and loss of appetite. Additionally, recent studies have shown that metformin reduces the intestinal dysbiosis of prediabetes. Therefore, the role of bioactive plant compounds, such as citrus flavonoids, which have multiple antidiabetic effects, has been investigated. These compounds have a regulatory influence on the microbiota in dysbiosis, improving the abundance of microorganisms, restructuring and rebalancing the intestinal microbial homeostasis.
Thus, the main objective of this study was to verify the association of the nutraceutical Eriomin® with metformin on the intestinal microbiota of individuals with prediabetes using a microbiome model, Simulator of Human Intestinal Microbial Ecosystem (SHIME®).
The experimental period in SHIME® was 6 weeks, divided into: Stabilization = 2 weeks, Control Period = 1 week, Intervention = 3 weeks, and the treatments were: Metformin 500 mg for 7 days); Eriomin® 200 mg + Metformin 500 mg, for 7 days; Eriomin® 500 mg + Metformin 500 mg, for 7 days. The composition of the intestinal microbiota obtained by sequencing the 16S rRNA gene and its metabolites, short chain fatty acids (SCFAs) and ammonium ions, was analyzed. Statistical analyzes were performed by ANOVA and Tukey's multiple comparison test, as well as bioinformatics analyzes for microbiota diversity.
The results showed a statistical difference (p=0.01) in bacterial communities regarding beta diversity, by unweighted Unifrac. In the metformin treatment, the taxonomic assignment performed at the genus level of the prediabetes microbiota showed an increase in Bifidobacterium, Lachonoclostridium, Coriobacteriaceae and Lachnospira. On the other hand, with the treatment Eriomin® 200 + Metformin 500, there was an increase in Subdoligranilum and Caproiciproducens, and finally the treatment with Eriomin® 500 + Metformin 500, there was an increase in Bacteroides, Subdoligranilum and Sutterella. All treatments showed an increase in SCFAs (p<0.01), but the best production of acetic and propionic acid was with 200 or 500 mg of Eriomin® + Metformin, and of butyric acid was with 500 mg of Eriomin® + Metformin. All treatments showed a decrease (p<0.01) of the ammonium ion. The most stimulated gender with Eriomin® + Metformin was Subdoligranulum. Recent studies have shown that the abundance of Subdoligranulum genera were positively correlated with HDL-cholesterol levels and negatively correlated with fat mass and inflammatory markers in humans.
Therefore, the combined treatment of metformin with Eriomin® constitutes a promising therapy for prediabetes, helping to reverse this metabolic condition and preventing the development to diabetes, which threatens to overwhelm global health supplies in the very near future.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper